[Relations between overweight, thrombophilia and cardiovascular risk]
A Craveri1, G Tornaghi, R Ranieri
1Corso Pareggiato di Semeiotica Medica dell'Università degli Studi di Milano, Ospedale San Paolo.
Annali Italiani Di Medicina Interna : Organo Ufficiale Della Societa Italiana Di Medicina Interna
|January 1, 1990
Summary
Obesity is linked to reduced plasma fibrinolytic activity, likely due to increased plasminogen activator inhibitor (PAI) levels. This may contribute to a thrombophilic state in obese individuals.
Area of Science:
- Biochemistry
- Physiology
- Medical Research
Background:
- Obesity is a growing global health concern.
- Impaired fibrinolytic activity is associated with thrombotic events.
- The relationship between obesity, fibrinolysis, and related markers requires further investigation.
Purpose of the Study:
- To investigate the correlation between Body Mass Index (BMI) and fibrinolytic system markers.
- To explore the potential link between obesity, plasminogen activator inhibitor (PAI), C-peptide, and fibrinolytic activity.
Main Methods:
- Cross-sectional study involving 71 healthy adults (aged 20-60).
- Measurements included Body Mass Index (BMI), plasminogen activator inhibitor (PAI) activity, C-peptide levels, and plasma fibrinolytic activity.
- Statistical analysis to determine correlations between variables.
Main Results:
- Significant negative correlation found between BMI and plasma fibrinolytic activity (r = -0.382, p < 0.005).
- Significant positive correlations observed between BMI and PAI (r = 0.353, p < 0.005) and between BMI and C-peptide (r = 0.694, p < 0.001).
- A positive correlation was also found between PAI and C-peptide (r = 0.404, p < 0.02).
Conclusions:
- Obesity is associated with decreased plasma fibrinolytic activity, potentially mediated by elevated PAI levels.
- Impaired fibrinolysis in obesity, possibly linked to hyperinsulinemia (indicated by C-peptide), may promote a thrombophilic state.
- These findings highlight a potential mechanism linking obesity to increased thrombotic risk.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:27Psychoneuroimmunology: Cardiovascular Disease
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...